41 completed. 41 Phase 3, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 41 | Completed 41 |
| Phase 2 | 11 | Completed 11 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Cannabinoids on Appetite in Scleroderma CBD oil, Placebo - Systemic Sclerosis, Malnutrition | Phase 3 | Completed | Khon Kaen University | 30 | 2022-11-09 | 2025-02-20 |
| Rituxmab Versus IL-6 in Treating ILD Rituximab, IL6 inhibitor - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Assiut University | 60 | 2021-12-01 | 2023-11-15 |
| Effects of Fractional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis CO2 Vaginal Laser - Systemic Sclerosis, Vulvovaginal Signs and Symptoms | Phase 2 / Phase 3 | Completed | IRCCS San Raffaele | 16 | 2020-05-01 | 2024-01-30 |
| Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) Placebo IV infusion, Iloprost Injection, for intravenous use - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 3 | Completed | Civi Biopharma, Inc. | 198 | 2019-10-14 | 2025-05-25 |
| A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis KHK4827, Placebo - Moderate to Severe Systemic Sclerosis | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 100 | 2019-05-23 | 2025-07-11 |
| Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis BOTOX® solution, Placebo group - Raynaud Phenomenon Secondary to Systemic Sclerosis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 91 | 2018-10-15 | 2022-02-10 |
| A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis Double-Blind Placebo, Double-Blind Rituximab - Scleroderma, Systemic, Skin Sclerosis | Phase 2 / Phase 3 | Completed | Tokyo University | 56 | 2017-12-04 | 2020-02-18 |
| Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease Mycophenolate mofetil, Placebo - Systemic Sclerosis, Scleroderma | Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 41 | 2016-10-01 | 2018-06-06 |
| A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) Placebo, Tocilizumab - Systemic Sclerosis | Phase 3 | Completed | Hoffmann-La Roche | 212 | 2015-11-20 | 2020-03-09 |
| A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Nintedanib, Placebo - Scleroderma, Systemic | Phase 3 | Completed | Boehringer Ingelheim | 580 | 2015-11-12 | 2019-12-13 |
| Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Onabotulinumtoxin A, sterile saline solution - Scleroderma, Raynaud's Syndrome | Phase 3 | Completed | Johns Hopkins University | 40 | 2015-01-01 | 2016-12-22 |
| Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Rituximab, Cyclophosphamide - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Royal Brompton & Harefield NHS Foundation Trust | 104 | 2014-11-01 | 2021-10-07 |
| "As Required" Oral Sildenafil in Raynaud's Phenomenon Sildenafil 40 mg, Sildenafil 80 mg, Placebo - Raynaud's Phenomenon | Phase 2 / Phase 3 | Completed | University Hospital, Grenoble | 41 | 2013-11-01 | 2016-01-18 |
| Gastroesophageal Reflux Treatment in Scleroderma Alginic acid, placebo (for domperidone), Domperidone - Gastroesophageal Reflux Disease, Systemic Sclerosis | Phase 3 | Completed | Khon Kaen University | 80 | 2013-06-01 | 2017-03-27 |
| Rituximab in Systemic Sclerosis Rituximab, Placebo (NaCl) - Systemic Sclerosis | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 22 | 2013-04-09 | 2025-11-20 |
| Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease Cyclophosphamide, Placebo - Systemic Sclerosis, Scleroderma | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 40 | 2013-01-14 | 2025-09-12 |
| A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis Placebo, tocilizumab [RoActemra/Actemra] - Sclerosis, Systemic | Phase 3 | Completed | Hoffmann-La Roche | 87 | 2012-03-01 | 2016-09-23 |
| A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Tadalafil, Placebo - Lung Diseases, Interstitial | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 40 | 2012-03-01 | 2015-04-21 |
| Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients macitentan 3mg, macitentan 10mg, placebo - Systemic Sclerosis, Ulcers | Phase 3 | Completed | Actelion | 289 | 2011-12-01 | 2015-01-06 |
| Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Sildenafil citrate, Placebo (Sugar pill) - Scleroderma, Systemic, Scleroderma, Diffuse | Phase 3 | Completed | Federal University of São Paulo | 41 | 2011-04-01 | 2016-12-05 |
Showing 20 of 41. Sign in to see all of them.
Scleroderma, Diffuse (24) · Raynaud Disease (12) · Lung Diseases, Interstitial (6) · Pulmonary Fibrosis (6) · Autoimmune Diseases (5) · digital ulcers (4) · Connective Tissue Diseases (3) · Arthritis (2) · Hypertension, Pulmonary (2) · Myositis (2) · Scleroderma, Limited (2) · Ulcer (2) · Anorexia (1) · Arthritis, Rheumatoid (1)
Skin Diseases (41) · Skin and Connective Tissue Diseases (41) · Connective Tissue Diseases (38) · Cardiovascular Diseases (14) · Vascular Diseases (14) · Embolism and Thrombosis (12) · Livedoid Vasculopathy (12) · Pathological Conditions, Signs and Symptoms (12) · Peripheral Vascular Diseases (12) · Respiratory Tract Diseases (12) · Skin Diseases, Vascular (12) · Thrombosis (12) · Lung Diseases (11) · Pathologic Processes (11)
Cyclophosphamide (5) · Bosentan (4) · Nitroglycerin (3) · Rituximab (3) · Sildenafil Citrate (3) · Tadalafil (3) · tocilizumab (3) · Iloprost (2) · Alginic Acid (1) · Botulinum Toxins (1) · Botulinum Toxins, Type A (1) · Domperidone (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Immunoglobulins, Intravenous (1) · Lidocaine (1)
Actelion (5) · Assistance Publique - Hôpitaux de Paris (3) · Johns Hopkins University (3) · MediQuest Therapeutics (3) · Sanjay Gandhi Postgraduate Institute of Medical Sciences (3) · Federal University of São Paulo (2) · Hoffmann-La Roche (2) · Khon Kaen University (2) · Allergan (1) · Assiut University (1) · Benesis Corporation (1) · Boehringer Ingelheim (1) · Civi Biopharma, Inc. (1) · Encysive Pharmaceuticals (1) · IRCCS San Raffaele (1)
United States (13) · France (8) · Canada (6) · India (5) · Japan (5) · United Kingdom (5) · Germany (4) · Italy (4) · Brazil (3) · Denmark (3) · Hungary (3) · Poland (3) · Thailand (3) · Argentina (2) · Australia (2)
Vikas Agarwal, MD, DM (2) · Alexandre WS Silva, PhD (1) · Aman Sharma, MD (1) · Anna Abou-Raya (1) · Ayumi Yoshizaki, MD, PhD (1) · Carin Dugowson, MD, MPH (1) · Chingching Foocharoen, M.D. (1) · Chingching Foocharoen, MD (1) · Daniel E. Furst, MD (1) · Darshan S Bhakuni, MD (1) · Fernando V Andrigueti, MD (1) · Fredrick M Wigley, M.D. (1)
PMID 37929840, PMID 33294861, PMID 33765691, PMID 16790698, PMID 17717203, PMID 17901414, PMID 17974598, PMID 18641099, PMID 19892673, PMID 20506355, PMID 20708086, PMID 20800376, PMID 20805294, PMID 20837499, PMID 21547897, PMID 22156609, PMID 23418384, PMID 23910617, PMID 25452309, PMID 25995322, PMID 26704522, PMID 26757749, PMID 27156934, PMID 27163986, PMID 27179107, PMID 28426903, PMID 28544580, PMID 28602891, PMID 28619061, PMID 28664834, PMID 29066464, PMID 29099620, PMID 29298160, PMID 29853453, PMID 29858547, PMID 30383134, PMID 30651141, PMID 31112379, PMID 31813058, PMID 32243207, PMID 32866440, PMID 33131208, PMID 33142016, PMID 33223487, PMID 33328257, PMID 33412120, PMID 33538094, PMID 34533286, PMID 34851799, PMID 35012623
2015 (2), U01HL060839 (1)